Porcilis M Hyo ID ONCE
Active substance
ATC code
Species
Pigs.
Indications
For the active immunisation of pigs to reduce pulmonary lesions and the decrease in daily weight gain during the finishing period due to infection caused by Mycoplasma hyopneumoniae.
Onset of immunity: 3 weeks after vaccination.
Duration of immunity: 22 weeks after vaccination.
Dose to be administered and administration route
Intradermal use.
Intradermal administration of 0.2 ml per animal preferably at the sides of the neck or along the muscles of the back using a multi-dose needle-free injection device for intradermal application of liquids suitable to deliver a “jet-stream” volume of vaccine (0.2 ml ± 10%) through the epidermal layers of the skin. A small, transient, intradermal lump observed after the intradermal application is indicative of the appropriate vaccination technique.
Safety and efficacy of Porcilis M Hyo ID ONCE have been demonstrated using the device IDAL.
Vaccination scheme:
Vaccinate once from an age of 2 weeks onwards.
Before using the vaccine allow it to reach room temperature (15 - 25 °C) and shake well before use.
Avoid introduction of contamination.
Adverse reactions
Pigs:
|
Very common (>1 animal / 10 animals treated): |
Elevated temperature1, injection site swelling2 |
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Lying down, malaise |
1A transient elevated temperature (mean 0.7 °C, in individual pigs up to 2 °C) very commonly occurs on the day of vaccination. The animals return to normal 1 to 2 days after the peak temperature is observed.
2A transient injection site swelling mostly consisting of hard non-painful button-like swellings of a diameter of up to 4 cm can be very commonly observed. In individual pigs redness and/or a biphasic pattern of the injection site swelling, consisting of an increase and decrease followed by another increase and decrease of the size, may be observed. The injection site swelling disappears completely within approximately 7 weeks after vaccination.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.
